Business Daily Media

Novel Chinese medicine for constipation developed by HKBU authorised by U.S. FDA for clinical trial

HONG KONG SAR - Media OutReach - 25 July 2023 - The Centre for Chinese Herbal Medicine Drug Development (CDD) of Hong Kong Baptist University (HKBU) has made significant progress in developing novel Chinese medicine for treating chronic constipation.

With its success in the Investigational New Drug Application to the U.S. Food and Drug Administration (FDA), CDD has been authorised to conduct a phase I clinical trial of the new drug. This is the first time that a new botanical drug developed in Hong Kong was authorised to conduct a clinical trial in the US.

Professor Bian Zhaoxiang (middle), Associate Vice-President (Chinese Medicine Development) and Director of the CDD; Ms Emily Au (left), Assistant Director (Research and Development) of the CDD; and Dr Lam Yan-yan (right), Assistant Professor of the CDD at HKBU, announce that CDD-2101, a novel Chinese medicine for treating chronic constipation, has been authorised by U.S. FDA to conduct a phase I clinical trial of the new drug in the US.
Professor Bian Zhaoxiang (middle), Associate Vice-President (Chinese Medicine Development) and Director of the CDD; Ms Emily Au (left), Assistant Director (Research and Development) of the CDD; and Dr Lam Yan-yan (right), Assistant Professor of the CDD at HKBU, announce that CDD-2101, a novel Chinese medicine for treating chronic constipation, has been authorised by U.S. FDA to conduct a phase I clinical trial of the new drug in the US.

The clinical trial will be launched later this year to evaluate the safety, tolerability, and pharmacokinetics profile of the new drug on healthy individuals.

Research based on traditional Chinese herbal formulation

A research team led by Professor Bian Zhaoxiang (middle), Ms Emily Au (left) and Dr Lam Yan-yan (right) develops CDD-2101, a novel Chinese medicine for treating chronic constipation based on the traditional Chinese herbal formulation “MaZiRenWan”.
A research team led by Professor Bian Zhaoxiang (middle), Ms Emily Au (left) and Dr Lam Yan-yan (right) develops CDD-2101, a novel Chinese medicine for treating chronic constipation based on the traditional Chinese herbal formulation “MaZiRenWan”.

Chronic constipation is a common gastrointestinal disorder affecting approximately 14% of the global population. Currently, many patients with chronic constipation are not completely satisfied with their current treatments due to side effects and/or limited efficacy. In response to the patients' needs for better therapeutics, CDD has been eyeing the international market and has developed a new drug called CDD-2101, which is based on previous pilot clinical studies and basic research on the traditional Chinese herbal formulation "MaZiRenWan".

The main ingredients of CDD-2101 include hemp seed, rhubarb, officinal magnolia bark, bitter apricot seed, bran stir-fried immature orange fruit, and white peony root. The HKBU research team collaborated with partners including the University of Chicago and the University of Macau to submit an Investigational New Drug Application for CDD-2101 according to the requirements for botanical drug development of the U.S. FDA and was authorised to conduct a phase I clinical trial.


Milestone of standardisation and internationalisation of Chinese medicine

Professor Alexander Wai, President and Vice-Chancellor of HKBU, said: "HKBU is committed to promoting the development of Chinese medicine, and conducting cutting-edge scientific and translational research in this area. The University received funding from the Innovation and Technology Commission's InnoHK initiative to establish the CDD in 2020, which significantly boosted our comprehensive capabilities in the research and development of Chinese medicine. The clinical trial in the US will provide us with invaluable experience in conducting clinical trials at Hong Kong's first Chinese Medicine Hospital in future."

Professor Bian Zhaoxiang, Associate Vice-President (Chinese Medicine Development), Director of the Clinical Division of the School of Chinese Medicine, and Director of the CDD at HKBU, said: "CDD-2101 is a novel drug developed by combining a traditional Chinese herbal formulation and advanced technologies, with research and manufacturing conducted in compliance with international standards. Obtaining U.S. FDA's authorisation to conduct a clinical trial for this new drug is an important milestone in the development of Chinese medicine in Hong Kong, and it reflects HKBU's capabilities in and dedication to promoting the standardisation and internationalisation of Chinese medicine."

Authorisation from the U.S. FDA was secured in April this year to conduct a phase I clinical trial of CDD-2101 in the US. The trial will start later this year and will recruit 20 healthy participants in the US. It will be a randomised, double-blinded, and placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics profile of the drug. Participants will take a single dose of CDD-2101 or a placebo and be monitored for 24 hours. The study will be conducted at a phase I clinical research centre in the US.

Phase I trial focuses on safety

The phase I clinical trial is expected to be completed in 2024, followed by a phase II study to collect the safety and efficacy data from patients with chronic constipation. A large-scale phase III study will then be launched to further evaluate the treatment efficacy of CDD-2101 in patients with chronic constipation, and monitor any unforeseeable side effects.

Professor Bian said: "The ultimate goal of the drug development programme is to collect sufficient safety and efficacy data, so that CDD-2101 can be evaluated and approved by the U.S. FDA as a new pharmaceutical for sale and marketing in the US. This is essential in establishing CDD-2101 as an internationally recognised, safe and effective drug for the treatment of chronic constipation. It is anticipated that another three to five years are needed to complete the phase II and III clinical trials, after which the data gathered during the animal studies and human clinical trials, together with details of the manufacturing of the drug, will be included in a New Drug Application to be submitted to the U.S. FDA for review."

The CDD, funded by the Innovation and Technology Commission's InnoHK initiative, is the first integrated Chinese medicine research and development centre at a local university. Located in the Hong Kong Science and Technology Parks and equipped with advanced facilities, the CDD aims to gather world-class partners to translate the wisdom of traditional Chinese medicine wisdom into pharmaceutical products that meet international standards. Since its establishment in 2020, the CDD has been focusing on innovative Chinese medicine research for gastrointestinal and immune-related diseases such as chronic constipation and ulcerative colitis.

Hashtag: #HKBU

The issuer is solely responsible for the content of this announcement.

News from Asia

Beloved Disney ∙ Pixar Characters Come to Life as 10 FURRY NICE Collectible Furry Friend Sets at 7-Eleven

Collect FunStamps on the New 7-Eleven App and Redeem for FREE HONG KONG SAR - Media OutReach Newswire - 21 November 2024 - Christmas is just around the corner and 7-Eleven is inviting all of your ...

Arbor Partners With Japanese Aomori Prefecture To Unveil A New Japanese-French Culinary Feast

HONG KONG SAR - Media OutReach Newswire - 21 November 202 - Aomori Crafts from Japan will collaborate with the Michelin 2-star restaurant Arbor to launch a limited menu starting November 22, lasti...

Hong Kong's premier ink art event UOB Art in Ink Festival returns this December, fostering art inclusivity

Featuring Hong Kong’s first ink art carnival InkFinity Fair with a blend of interactive games and art engagements HONG KONG SAR - Media OutReach Newswire - 21 November 2024 - UOB Art Academy and U...

PT. Eka Mas Republik (MyRepublic) Celebrates Double Recognition at ACES Awards

BANGKOK, THAILAND - Media OutReach Newswire - 22 November 2024 - PT. Eka Mas Republik, operating as MyRepublic, has received two prestigious honours at the 2024 Asia Corporate Excellence & Sus...

Elsie’s Kitchen Unveils Christmas Catering Menus to Elevate Holiday Celebrations

SINGAPORE - Media OutReach Newswire - 22 November 2024 - Elsie's Kitchen is thrilled to announce the launch of the highly anticipated Christmas Catering Menu, available for pre-order from November...

Michelin Showcases Its Commitment to Innovating for a Sustainable Future at Asia Pacific Media Day 2024 in Thailand

BANGKOK, THAILAND - Media OutReach Newswire - 22 November 2024 - Michelin, world-leading manufacturer of life-changing composites and experiences, welcomed international media to its two-day Asia ...

MIPS Releases P8700, Industry’s First High-Performance AI-Enabled RISC-V Automotive CPU for ADAS and Autonomous Vehicles

SAN JOSE, CALIFORNIA - Media OutReach Newswire - 22 November 2024 - MIPS, a leading developer of efficient and configurable IP compute cores, announced today the general availability (GA) launch ...

AJINOMOTO Presents Authentic Taste of Japan with Launch of "HANE GYOZA PORK" in Singapore

SINGAPORE - Media OutReach Newswire - 22 November 2024 - AJINOMOTO SINGAPORE PTE. LTD. announced the launch of the frozen food "HANE GYOZA PORK" today, the first made-in-Japan pork gyoza available...

HKPC Wins Gold Award in Government PR Category at 20th China Golden Awards for Excellence in Public Relations

HONG KONG SAR - Media OutReach Newswire - 22 November 2024 - The Hong Kong Productivity Council (HKPC) recently won the gold award in the "Government Public Relations" category at the 20th China ...

UFC® FIGHT NIGHT MACAU at Galaxy Macau A Thrilling Night of Fights Set for Galaxy Arena on November 23

The Press Conference for the Event Was Held This Afternoon at the Galaxy International Convention Center. The Main Event and Co-Main Event Athletes Attended and Spoke to Media. MACAU SAR - Media O...

Tips For Choosing The Ideal Coffee Table For Your Living Room

In recent years, coffee tables have gained popularity in home decor, thanks to their versatility and stylish appeal. Available in a wide range of ...

Property

Deep Blue Company marks 10 years of operation with major milestone of largest national market share

The Australian pioneer of digital conveyancing is now 20 times larger than the nearest competitor in the sale-to-settlement category following pla...

Property

Navigate Agile Certifications for Project Management Professionals

Agile methodology is increasingly relevant for individuals and organizations seeking to stay ahead in an ever-evolving digital landscape. This set of ...

Business Training

The Fast Track to Home Selling: A Comprehensive Guide to Quick Sales

The pace of the real estate market varies widely based on several factors, including location, property value, and current economic climates. For ma...

Property

6 Ways to Improve Customer Experience

When it comes to a great customer experience, how you treat your customers, the quality of your products or services, and the overall customer jou...

Business Training

Reventon’s Brick by Brick Charity Build to Auction Fully Furnished Family Home

Imagine transforming a $1 million dream home into hope and security for countless Australians in need. Imagine no more. In a groundbreaking act o...

Property